🧴 Retatrutide AQ – 30 MG / 3 mL Pen – ZPHC PHARMA
🧪 Product Type
Advanced Peptide – Triple Receptor Agonist (GLP-1 / GIP / Glucagon)
Active Ingredient: Retatrutide
Concentration: 30 MG / 3 mL
Form: Pre-filled injectable pen (aqueous solution)
Manufacturer: ZPHC PHARMA
📄 Description
Retatrutide AQ by ZPHC PHARMA is a next-generation injectable peptide therapy formulated in a ready-to-use prefilled pen, containing 30 MG of Retatrutide in 3 mL of aqueous solution. It functions as a triple receptor agonist, simultaneously targeting:
- GLP-1 (Glucagon-like peptide-1)
- GIP (Gastric inhibitory peptide)
- Glucagon receptors
This unique triple action has demonstrated promising results in metabolic research, especially in obesity management, type 2 diabetes, and energy regulation.
✅ Key Benefits
-
🔥 Powerful Fat-Burning Potential
Increases metabolic rate and promotes lipolysis -
🍽️ Appetite Suppression & Satiety
Helps reduce caloric intake through central appetite regulation -
💉 Convenient Pre-Filled Pen
Easy and precise administration without reconstitution -
📉 Improved Blood Glucose Control
Enhances insulin sensitivity and lowers fasting glucose -
⚙️ Supports Weight Management & Energy Balance
Ideal for research involving complex metabolic disorders
⚙️ Mechanism of Action
Retatrutide mimics multiple gut-derived hormones, activating receptors involved in:
- Glucose homeostasis
- Fat metabolism
- Energy expenditure
- Appetite regulation
This synergy helps deliver comprehensive metabolic modulation in experimental models.
💉 Suggested Research Use (For Laboratory Research Only)
- Dosage: Varies based on protocol (typically once weekly)
- Administration: Subcutaneous injection via prefilled pen
- No mixing or preparation required
- Monitor for metabolic markers, appetite response, and body composition changes
⚠️ Potential Side Effects
- Nausea or mild GI discomfort (usually subsides over time)
- Headache or dizziness
- Injection site irritation
- Temporary fatigue or appetite loss
Side effects are generally dose-dependent and resolve with continued use.
🚫 Contraindications / Exclusion in Research
- History or risk of thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Severe GI disorders
- Known hypersensitivity to peptide-based therapies
🛒 Product Information
- Product Name: Retatrutide AQ
- Dosage: 30 MG in 3 mL solution
- Device: Prefilled injection pen
- Brand: ZPHC PHARMA
- Intended Use: For Research Purposes Only – Not for Human Consumption
- Storage: Refrigerate at 2°C–8°C; do not freeze
- Shipping: Available via certified research supply channels
| Brands | ZPHC PHARMA |